Please check your internet connection and try again.
# L-Ornithine L-Aspartate (Hepamerz)
## Overview
L-Ornithine L-Aspartate (LOLA) is an amino acid derivative used in the management of hyperammonemia associated with liver dysfunction. It is believed to promote ammonia detoxification by stimulating the urea cycle and glutamine synthesis.
## Primary Indications
* Treatment of latent and manifest hepatic encephalopathy.
* Management of hyperammonemia in patients with liver disease.
## Adult Dosing
* **Hepatic Encephalopathy/Hyperammonemia:** Typically administered intravenously (IV) at a dose of **10-30 grams per day**, divided into 2-3 infusions.
* **Loading dose:** Some protocols suggest an initial loading dose of up to 20 grams over 24 hours.
* **Maintenance:** Doses can be adjusted based on ammonia levels and clinical response. Continuous infusions may also be used.
* **Oral Formulations:** Oral formulations are available and typically dosed at **6-18 grams per day**, divided into 2-3 doses.
*Note: Specific dosing regimens may vary based on the severity of hepatic encephalopathy, degree of hyperammonemia, and local institutional protocols.*
## Pediatric Dosing
* There is **limited established pediatric dosing** for L-Ornithine L-Aspartate. Dosing in children should be guided by expert consultation and careful monitoring of ammonia levels and clinical response.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustments are typically recommended due to the primary metabolism in the liver and excretion by the kidneys. However, caution may be warranted in severe renal impairment.
* **Hepatic Impairment:** This drug is used in patients with hepatic impairment; dose adjustments are based on ammonia levels and clinical response.
## Contraindications
* Severe hypersensitivity to L-ornithine L-aspartate or any of its excipients.
* Severe renal insufficiency (creatinine clearance < 25 mL/min) due to potential accumulation of urea.
* Rarely, patients with certain metabolic disorders may have contraindications.
## Adverse Effects
* **Common:** Nausea, vomiting, abdominal discomfort, flatulence.
* **Less Common:** Dizziness, headache, fatigue, skin rash.
* **Rare:** Allergic reactions.
## Key Drug Interactions
* No significant drug interactions have been widely reported. However, concurrent use of other medications affecting ammonia levels or hepatic function should be monitored.
## Monitoring
* **Serum ammonia levels:** Regularly monitor to assess efficacy and guide dosing.
* **Renal function:** Monitor serum creatinine, especially in patients with pre-existing renal issues or at risk.
* **Hepatic function tests:** Monitor liver enzymes and bilirubin.
* **Clinical status:** Assess for improvement in neurological symptoms of hepatic encephalopathy.
## Clinical Pearls
* LOLA works by facilitating the conversion of ammonia into urea and glutamine, thereby lowering serum ammonia concentrations.
* It is most effective when ammonia levels are elevated due to impaired liver function.
* Oral administration should be taken with meals to improve tolerability.
* Intravenous administration is typically given as a slow infusion to minimize side effects.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the current prescribing information and your institution's guidelines before administering any medication.
